1. Home
  2. ZURA vs LNSR Comparison

ZURA vs LNSR Comparison

Compare ZURA & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zura Bio Limited

ZURA

Zura Bio Limited

HOLD

Current Price

$3.51

Market Cap

137.2M

Sector

Health Care

ML Signal

HOLD

Logo LENSAR Inc.

LNSR

LENSAR Inc.

HOLD

Current Price

$10.27

Market Cap

142.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZURA
LNSR
Founded
2022
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical Electronics
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
137.2M
142.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ZURA
LNSR
Price
$3.51
$10.27
Analyst Decision
Strong Buy
Hold
Analyst Count
9
1
Target Price
$11.38
$15.00
AVG Volume (30 Days)
408.9K
75.6K
Earning Date
11-13-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$59,141,000.00
Revenue This Year
N/A
$30.80
Revenue Next Year
N/A
$33.09
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.02
52 Week Low
$0.97
$7.13
52 Week High
$4.68
$17.31

Technical Indicators

Market Signals
Indicator
ZURA
LNSR
Relative Strength Index (RSI) 44.69 43.36
Support Level $3.57 $9.56
Resistance Level $3.95 $10.48
Average True Range (ATR) 0.27 0.37
MACD -0.07 0.07
Stochastic Oscillator 0.43 74.31

Price Performance

Historical Comparison
ZURA
LNSR

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

About LNSR LENSAR Inc.

LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.

Share on Social Networks: